The DLG5 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DLG5 gene. This product offers a heterogeneous pool of gene-disrupted cells, providing a robust tool for functional studies while avoiding clonal artifacts. It is designed for researchers investigating DLG5-dependent mechanisms in a near-haploid background.
The host HAP1 cell line originates from the KBM-7 chronic myeloid leukemia (CML) lineage and exhibits a near-haploid karyotype, which greatly simplifies genetic manipulation and phenotypic analysis. HAP1 cells display a fibroblast-like morphology and grow as an adherent monolayer, characteristics that support a wide range of cell-based assays, including imaging, migration, and biochemical interaction studies. Their haploid nature ensures efficient knockout generation and stable maintenance of gene disruptions.
DLG5 encodes a membrane-associated guanylate kinase scaffold protein critical for cell polarity and tight junction assembly. It is recruited to apical junctions through interactions with cadherin?Ccatenin complexes and is regulated by Wnt5a and the Par3/Par6/aPKC polarity machinery. DLG5 scaffolds PALS1, PATJ, LIN7C, CRB3, and MPP5 to cluster occludin and claudins, thereby maintaining epithelial barrier integrity. Additionally, DLG5 transduces signals via JNK and Rho GTPases to coordinate cytoskeletal dynamics.
In HAP1 cells, DLG5 disruption enables dissection of its scaffolding functions without the complexity of polarized epithelia. The near-haploid background facilitates unambiguous genotype?Cphenotype correlation, making these polyclonal knockout cells ideal for biochemical studies, protein interaction mapping, and rescue experiments. They provide a clean genetic system to explore DLG5??s role in cell adhesion and polarity signaling.
Key applications include examination of intestinal barrier dysfunction in Crohn??s disease, drug target validation for inflammatory bowel disease, and mechanistic studies of colorectal cancer progression. Assays such as Western blotting for tight junction regulators, immunofluorescence, co-immunoprecipitation, and migration/invasion assays are directly compatible. The polyclonal population also supports high-throughput screens for modulators of DLG5-mediated pathways. For further information, contact Ascent Research.
